サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1758981

淋病治療薬の世界市場

Gonorrhea Therapeutics

出版日
ページ情報
英文 140 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.05円
淋病治療薬の世界市場
出版日: 2025年06月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 140 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

淋病治療薬の世界市場は2030年までに28億米ドルに達する見込み

2024年に20億米ドルと推定される淋病治療薬の世界市場は、2024～2030年の分析期間においてCAGR 5.7%で成長し、2030年には28億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである単剤療法は、CAGR 6.7%を記録し、分析期間終了までに19億米ドルに達すると予測されます。併用療法セグメントの成長率は、分析期間中CAGR 4.0%と推定されます。

米国市場は5億3,170万米ドルと推定、中国はCAGR 5.5％で成長予測

米国の淋病治療薬市場は、2024年に5億3,170万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億5,100万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.2％と4.9％と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の「淋病治療薬」市場- 主要動向と促進要因のまとめ

淋病治療薬市場が急成長し、世界的に注目されている理由とは？

世界の淋病治療薬市場は、特に抗生物質耐性の増加に伴い、公衆衛生上の課題としてこの病気が再浮上していることから、再び注目を集めています。淋病は、淋菌によって引き起こされる一般的な性感染症（STI）であり、毎年数百万人が罹患しています。この感染症は一般的に治療可能であるが、かつては治療の主流であったセファロスポリンやアジスロマイシンに対する耐性が強まり、新たな治療戦略が急務となっています。世界保健機関（WHO）と米国疾病予防管理センター（CDC）は「スーパー淋菌」株に関する警告を発し、薬剤開発、診断、世界のSTIサーベイランスプログラムへの投資拡大を促しています。

薬剤耐性淋菌治療の情勢を変えつつあるイノベーションとは？

抗菌薬耐性の増加に対応するため、製薬企業や研究開発機関は淋病に対する次世代治療法の開発に向けた取り組みを加速させています。ゾリフロダシンやゲポチダシンなどの新規抗生物質は現在臨床試験が進んでおり、多剤耐性株に対して有望視されています。一方、既存薬の再利用、二剤併用療法、併用治療などが、有効性を高め耐性発現を遅らせるために検討されています。バイオテクノロジー企業は、モノクローナル抗体、バクテリオファージ療法、宿主指向性治療薬など、抗生物質以外のアプローチも研究しています。さらに、迅速なPOC（ポイント・オブ・ケア）診断により早期発見が可能になり、臨床医がより効果的に治療を調整できるようになっています。

地域の医療制度と啓発キャンペーンは市場力学にどのような影響を与えるか？

淋病の負担は低・中所得地域、特にサハラ以南のアフリカ、東南アジア、ラテンアメリカの一部で最も大きく、診断や治療へのアクセスが限られていることが治療の妨げになっています。しかし、北米や欧州のような高所得地域でも症例の増加が報告されており、その一因は、監視システムがより強固になり、社会的認知度が高まったことにあります。政府主導のSTI予防対策、性的健康教育、検査拡大が、これらの地域における治療需要を牽引しています。無料または助成金による治療を提供するプログラムは、STIにまつわる偏見をなくす取り組みと相まって、診断率やタイムリーな治療を増加させています。世界の旅行や移住の状況は複雑さを増し、国境を越えた感染や国際的な協調対応の必要性を助長しています。

淋病治療薬市場の主な成長促進要因と障害は何か？

淋病治療薬市場の成長の原動力は、感染率の増加、緊急の公衆衛生上の義務、新たな医薬品介入を必要とする耐性株の出現です。性の健康に対する意識の高まり、STI対策に対する政府の資金援助、調査における世界の協力が市場拡大を支えています。しかし、抗生物質の研究開発ペースの遅さ、規制上のハードル、開発コストの高さ、製薬会社がSTI関連製品を追求する商業的インセンティブの制限など、大きな障壁も存在します。さらに、STIに関連する社会的烙印は、過少報告や治療の遅れにつながり、市場力学を複雑にしています。それにもかかわらず、世界の保健機関からの圧力の高まりや、診断薬と医薬品開発の両方における技術革新は、淋病治療薬を推進する上で必要な新たな後押しとなっています。

セグメント

治療法（単剤療法、併用療法）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の合計42社）

  • AbbVie Inc.
  • Alopexx Pharmaceuticals
  • Amgen Inc.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company
  • Biolytics Pharma
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • Danaher Corporation
  • Debiopharm International SA
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Entasis Therapeutics
  • Evofem Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Hologic, Inc.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Microbiotix, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Summit Therapeutics plc
  • Teva Pharmaceutical Industries Ltd.
  • Therapyx, Inc.

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP37013

Global Gonorrhea Therapeutics Market to Reach US$2.8 Billion by 2030

The global market for Gonorrhea Therapeutics estimated at US$2.0 Billion in the year 2024, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Monotherapy, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Combination Therapy segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$531.7 Million While China is Forecast to Grow at 5.5% CAGR

The Gonorrhea Therapeutics market in the U.S. is estimated at US$531.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$451.0 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global "Gonorrhea Therapeutics" Market - Key Trends & Drivers Summarized

Why Is the Gonorrhea Therapeutics Market Regaining Urgency and Global Attention?

The global gonorrhea therapeutics market is regaining attention as the disease re-emerges as a public health challenge, particularly with rising antibiotic resistance. Gonorrhea, a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, continues to affect millions of individuals annually, with the highest prevalence among sexually active young adults. While the infection is typically treatable, growing resistance to cephalosporins and azithromycin-once the mainstays of treatment-has created an urgent need for new therapeutic strategies. The World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention (CDC) have issued warnings about “super gonorrhea” strains, prompting increased investment in drug development, diagnostics, and global STI surveillance programs.

What Innovations Are Reshaping the Treatment Landscape for Drug-Resistant Gonorrhea?

In response to rising antimicrobial resistance, pharmaceutical companies and research institutions are accelerating efforts to develop next-generation therapies for gonorrhea. Novel antibiotics, such as zoliflodacin and gepotidacin, are currently in advanced clinical trials and show promise against multi-drug resistant strains. Meanwhile, repurposing of existing drugs, dual-therapy regimens, and combination treatments are being explored to enhance efficacy and delay resistance onset. Biotech firms are also investigating non-antibiotic approaches, including monoclonal antibodies, bacteriophage therapy, and host-directed therapeutics. Additionally, rapid point-of-care diagnostics are improving early detection and allowing clinicians to tailor treatments more effectively-critical for managing resistant infections and limiting disease transmission.

How Do Regional Health Systems and Awareness Campaigns Affect Market Dynamics?

The burden of gonorrhea is highest in low- and middle-income regions, particularly Sub-Saharan Africa, Southeast Asia, and parts of Latin America, where limited access to diagnostics and care impedes treatment. However, high-income regions like North America and Europe are also reporting a rise in cases, partly due to more robust surveillance systems and greater social awareness. Government-led STI prevention initiatives, sexual health education, and expanded testing are driving therapeutic demand in these areas. Programs offering free or subsidized treatment, combined with efforts to reduce stigma around STIs, are also increasing diagnosis rates and timely care. The global travel and migration landscape adds complexity, contributing to cross-border transmission and the need for coordinated international responses.

What Are the Primary Growth Drivers and Obstacles in the Gonorrhea Therapeutics Market?

The growth in the gonorrhea therapeutics market is driven by increasing infection rates, urgent public health mandates, and the emergence of resistant strains that demand new pharmaceutical interventions. Rising awareness of sexual health, government funding for STI control, and global collaboration in research are supporting market expansion. However, significant barriers persist, including the slow pace of antibiotic R&D, regulatory hurdles, high development costs, and limited commercial incentives for pharma companies to pursue STI-related products. Additionally, the social stigma associated with STIs can lead to underreporting and delayed treatment, complicating market dynamics. Nonetheless, growing pressure from global health agencies and innovation in both diagnostics and drug development signal a renewed and necessary push in advancing gonorrhea therapeutics.

SCOPE OF STUDY:

The report analyzes the Gonorrhea Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Monotherapy, Combination Therapy); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Alopexx Pharmaceuticals
  • Amgen Inc.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company
  • Biolytics Pharma
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • Danaher Corporation
  • Debiopharm International SA
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Entasis Therapeutics
  • Evofem Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Hologic, Inc.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Microbiotix, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Summit Therapeutics plc
  • Teva Pharmaceutical Industries Ltd.
  • Therapyx, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Gonorrhea Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Antimicrobial-Resistant Gonorrhea Strains Drives Urgency for New Therapeutics
    • Pipeline Expansion of Dual-Action Antibiotics Strengthens Business Case for R&D in STI Therapies
    • Increased Government Funding and WHO Priority Designation Throw Spotlight on Gonorrhea Research
    • Advancements in Rapid Diagnostic Tools Accelerate Prescription of Targeted Treatments
    • Public Health Campaigns and STI Awareness Programs Sustain Demand for Accessible Therapies
    • Clinical Trials of Novel Antibiotic Classes and Phage Therapy Open New Treatment Frontiers
    • Global Urbanization and High-Risk Population Growth Expand Therapeutic Use Cases
    • Inclusion of Gonorrhea Treatments in National Reimbursement Lists Improves Accessibility
    • Regulatory Fast-Track Approvals for Novel Antimicrobials Encourage Industry Participation
    • Expansion of Telehealth and Online Prescriptions Increases Market Reach of Therapeutic Providers
    • Cross-Sector Collaboration with NGOs and Public Health Bodies Drives Distribution in Low-Income Regions
    • Surveillance and Resistance Monitoring Systems Inform Pipeline and Post-Market Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gonorrhea Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Gonorrhea Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Monotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Monotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • JAPAN
    • Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • CHINA
    • Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • EUROPE
    • Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Gonorrhea Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • FRANCE
    • Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • GERMANY
    • Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Rest of Europe 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Gonorrhea Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Therapy - Monotherapy and Combination Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of World 6-Year Perspective for Gonorrhea Therapeutics by Therapy - Percentage Breakdown of Value Sales for Monotherapy and Combination Therapy for the Years 2025 & 2030
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Gonorrhea Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of World 6-Year Perspective for Gonorrhea Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2025 & 2030

IV. COMPETITION